A 2025 52-week randomized trial in adults with heterozygous familial hypercholesterolemia (HeFH) found that daily oral Enlicitide 20 mg reduced low-density lipoprotein (LDL) cholesterol by an average of 58% at 24 weeks and maintained about a 55% reduction at 52 weeks versus placebo.
November 21, 2025
high
temporal
Global randomized clinical trial of Enlicitide in adults with genetically elevated LDL cholesterol already on lipid-lowering therapy.
Merck stated that there were no approved U.S. monovalent single-antigen vaccines for measles, mumps, or rubella as of 2025-10-06.
October 06, 2025
high
regulatory
Manufacturer statement about available vaccine approvals in the United States.
Merck stated that evidence suggests use of combination vaccines for measles, mumps, and rubella improves childhood vaccination outcomes by increasing both completion (receipt of all recommended doses) and compliance (age-appropriate administration) rates.
October 06, 2025
high
clinical_evidence
Claim about the impact of combination vaccines on vaccination completion and timeliness.